This company has been acquired
Covetrus Past Earnings Performance
Past criteria checks 0/6
Key information
-7.8%
Earnings growth rate
-9.8%
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | 7.1% |
Return on equity | -0.9% |
Net Margin | -0.3% |
Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Covetrus GAAP EPS of -$0.03 misses by $0.06, revenue of $1.22B in-line
Aug 04Clayton, Dubilier & Rice/TPG Are Not Offering Fair Value To Covetrus Shareholders
Jun 02Covetrus, Inc.'s (NASDAQ:CVET) Intrinsic Value Is Potentially 98% Above Its Share Price
May 02Are Investors Undervaluing Covetrus, Inc. (NASDAQ:CVET) By 40%?
Jan 07We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt
Oct 21An Intrinsic Calculation For Covetrus, Inc. (NASDAQ:CVET) Suggests It's 37% Undervalued
Sep 16Estimating The Intrinsic Value Of Covetrus, Inc. (NASDAQ:CVET)
May 31Covetrus, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Is Covetrus (NASDAQ:CVET) Using Too Much Debt?
May 05Covetrus, Inc.: Well Positioned To Enjoy Market Crosscurrents
Apr 30Who Has Been Selling Covetrus, Inc. (NASDAQ:CVET) Shares?
Feb 26We Think Covetrus (NASDAQ:CVET) Has A Fair Chunk Of Debt
Jan 22Covetrus reports Q4 net sales of prescription management business
Jan 13Covetrus (NASDAQ:CVET) Shareholders Have Enjoyed An Impressive 106% Share Price Gain
Dec 18Covetrus, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 12Covetrus Q3 2020 Earnings Preview
Nov 09Revenue & Expenses BreakdownBeta
How Covetrus makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 22 | 4,649 | -13 | 723 | 0 |
31 Mar 22 | 4,621 | -40 | 728 | 0 |
31 Dec 21 | 4,575 | -54 | 714 | 0 |
30 Sep 21 | 4,575 | -56 | 709 | 0 |
30 Jun 21 | 4,539 | -90 | 714 | 0 |
31 Mar 21 | 4,376 | -13 | 685 | 0 |
31 Dec 20 | 4,339 | -26 | 698 | 0 |
30 Sep 20 | 4,225 | -19 | 700 | 0 |
30 Jun 20 | 4,117 | -940 | 630 | 0 |
31 Mar 20 | 4,100 | -996 | 688 | 0 |
31 Dec 19 | 3,976 | -980 | 661 | 0 |
30 Sep 19 | 3,871 | -948 | 576 | 0 |
30 Jun 19 | 3,776 | 27 | 587 | 0 |
31 Mar 19 | 3,772 | 65 | 504 | 0 |
29 Dec 18 | 3,778 | 101 | 485 | 0 |
30 Sep 18 | 3,791 | 69 | 547 | 0 |
30 Jun 18 | 3,776 | 74 | 543 | 0 |
31 Mar 18 | 3,649 | 67 | 532 | 0 |
30 Dec 17 | 3,580 | 64 | 460 | 0 |
31 Dec 16 | 3,353 | 70 | 489 | 0 |
26 Dec 15 | 2,978 | 60 | 418 | 0 |
Quality Earnings: CVET is currently unprofitable.
Growing Profit Margin: CVET is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CVET is unprofitable, and losses have increased over the past 5 years at a rate of 7.8% per year.
Accelerating Growth: Unable to compare CVET's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CVET is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (1.9%).
Return on Equity
High ROE: CVET has a negative Return on Equity (-0.85%), as it is currently unprofitable.